Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
What is your approach to evaluation and management of GERD in a patient with IPF?
How frequently do you monitor CT scans, PFTs, and TTEs in patients with ILA or mild ILD?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
How often do you monitor pulmonary function tests in patients with fibrotic lung disease?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
